XWXin Wei Wang

Xin Wei Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2025,2026)

Xin Wei Wang has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Marshonna Forgues

    National Cancer Institute

    66 shared publications
  • Anuradha Budhu

    Liver Cancer Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA

    54 shared publications
  • Hien Dang

    Department of Surgery, Thomas Jefferson University, Philadelphia, PA, USA; Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA

    39 shared publications
  • Subreen Khatib

    24 shared publications
  • Dana A. Dominguez

    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA; Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA

    22 shared publications
  • Sean P. Martin

    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

    21 shared publications

Latest Publications

  • Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity

    by Xin Wei Wang, Chi-Ping Day, Eugene V. Koonin

    The connections between viruses and cancer have historically been studied in the context of viral oncogenesis. For decades, tumour virology has focused on oncogenic viruses such as hepatitis B virus, hepatitis C virus, human papillomavirus, Epstein-Barr virus, human T cell leukaemia virus type 1, Kaposi sarcoma-associated herpesvirus and Merkel cell polyomavirus, elucidating their oncogenic mechanisms, which include mutagenesis, chronic inflammation and immune evasion. However, the human virome is vast and complex, and this oncogenesis-centred view has overshadowed the possibility that certain viral exposures enhance antitumour immunity. Through millions of years of coevolution with animal hosts, the virome, consisting of diverse bacteriophages and eukaryotic viruses, including endogenous retroviruses, appear to have evolved strategies for coexistence that shape immune development and potentiate host surveillance pathways capable of recognizing and eliminating cancer cells. Non-oncogenic viruses can prime innate and adaptive immune responses, mimic tumour antigens and modulate the expression of immune checkpoints, as exemplified by the association of the enterovirus and rhinovirus CE1 epitope with protective liver cancer immunity. Moreover, endogenous retroviruses, naturally occurring oncolytic viruses and microbiome-associated phages may act as allies in cancer control. This Review explores the emerging evidence for viral anticancer immunity, its underlying mechanisms, and implications for a virome-guided framework for cancer prevention including new approaches to risk assessment, immune-based therapeutics and applications in low-resource settings.


  • Open Access

    Enteroviral epitope mimicry enables NK cell-mediated targeting of ASPH in hepatocellular carcinoma

    by Man Hsin Hung, Qin Li, Limin Wang, Marshonna Forgues, Andrew S. Lee, Lisa M Jenkins, Tapan K. Maity, Jesse Buffington, Jittiporn Chaisaingmongkol, Siritida Rabibhadana, et al.

    Cancer development is shaped by host-microbe interactions, including viral infections. While several viruses are established oncogenic drivers, their potential protective roles in cancer remain unclear. Here we identify a dominant antibody response to CE1, a consensus epitope of enterovirus and rhinovirus, that is associated with reduced hepatocellular carcinoma (HCC) incidence and mortality. Anti-CE1 antibodies selectively recognize HCC cells and mediate anti-tumor activity through NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Mechanistically, anti-CE1 antibodies cross-react with aspartate β-hydroxylase (ASPH), with CE1-ASPH sequence homology underpinning tumor recognition and cytotoxicity. Clinically, ASPH is aberrantly upregulated in HCC and correlates with inferred NK cell-associated ADCC activity and improved survival in CE1-seropositive patients. Collectively, these findings reveal a mechanism by which antiviral humoral immunity confers cancer protection through molecular mimicry and highlight anti-CE1 immunity as a potential therapeutic strategy in HCC.


  • Open Access

    Multimodal Approach for Identification and Validation of Hepatocellular Carcinoma Targets for Radiotheranostics

    by Philip Homan, Joon-Yong Chung, Woonghee Lee, Divya Nambiar, Julia Sheehan-Klenk, Hima Makala, Stanley Fayn, Orit Jacobson, Arthur Paden King, Kyungeun Kim, et al.

    Identifying tumor selective targets is critical for the development of precision diagnostic and therapeutic agents in oncology. Despite advances in precision oncology elsewhere, there are no FDA-approved hepatocellular carcinoma (HCC)-selective treatments. HCC is the most common type of liver cancer and accounts for significant morbidity and mortality worldwide. Here, we sought to integrate bulk (371 cases) and single cell RNA sequencing (scRNAseq, n =2 datasets, 34 cases, 102,956 cells) of patient samples to enrich for molecules that are overexpressed in HCC, which could serve as HCC-selective targets. To guide definitions of tumor and normal cell clusters with higher fidelity, we also imported a normal liver scRNAseq dataset. Using this integrated approach, we identified several HCC-selective plasma membrane molecules. To validate these targets, we performed immunohistochemical staining of HCC and normal tissue microarrays and confirmed HCC-selective staining of identified targets. Next, we verified the presence of these targets in several commercially available HCC cell lines by flow cytometry and western blot. Finally, we designed, engineered, and tested novel antibody-based positron emission tomography (immunoPET) agents to these targets in various murine models of liver cancer. Our findings confirm that we can leverage this multimodal approach to identify and validate of HCC-selective targets, which can be used to develop tumor-selective diagnostic and therapeutic radiopharmaceuticals, or radiotheranostics, and other precision oncology agents. One Sentence Summary: A multimodal pipeline defines and validates tumor-selective surface targets for radiotheranostic use in hepatocellular carcinoma.

  • Open Access

    Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinoma

    by Shay Behrens, Whitney Leet Do, Limin Wang, Mahler Revsine, Evan Maestri, Aleesha Jacob, Ching-Wen Chang, Marshonna Forgues, Atlas Mashayekhi Sardoo, Anuradha Budhu, et al.

    Immune checkpoint inhibition (ICI) has become a first-line treatment strategy for advanced hepatocellular carcinoma (HCC). However, treatment efficacy remains varied, and there are no reliable biomarkers of response. We used phage immunoprecipitation sequencing technology to measure circulating viral and bacterial antibodies as a biomarker of ICI response. The XGBoost Cox-proportional hazard model identified 23 viral and bacterial strains associated with survival. An antigen score developed from the 23 reactive microbial peptides significantly predicted overall survival (HR: 81.7, [95% CI]: 9.88 to 10,690.96, p<0.0001) and a high antigen score was predictive of progressive disease (HR: 4.03, [95% CI]: 0.78 to 20.87, p=0.09). The time-dependent area under the curve was 0.8 at 1 year. Findings were validated in an independent cohort and confirmed the antigen score association with survival (HR: 2.38, [95% CI 0.98 to 5.76, p=0.055). Our results suggest a unique microbial reactivity profile may serve as a potential biomarker of ICI response in patients with HCC.


  • Open Access

    Urinary pesticide profiles and liver disease risk in Thailand: a machine-learning risk-prediction model

    by Daxesh Patel, Christopher Loffredo, Majda Haznadar, Mohammed Khan, Amelia Parker, Benjarath Pupacdi, Siritida Rabibhadana, Panida Navasumrit, Nirush Lertprasertsuke, Anon Chotirosniramit, et al.

    Background: Building on evidence linking urinary glyphosate to chronic liver disease (CLD) and hepatocellular carcinoma (HCC), we developed urinary pesticide profiling integrated with machine learning risk prediction (MLRP) to stratify risk in high-exposure populations. Methods: We conducted a case–control study within the Thailand Initiative in Genomics and Expression Research for Liver Cancer (TIGER-LC; 2011–2016; n=593): 228 CLD, 116 HCC, and 249 controls. Eight urinary pesticides were quantified by LC–MS/MS (pendimethalin, oxadiazon, metsulfuron-methyl, butachlor, 2,4-dichlorophenoxyacetic acid [2,4-D], cypermethrin, flocoumafen, bromadiolone). A composite Pesticide Load Score (PLS), with and without glyphosate, estimated burden. Two predictive models were developed: a logistic-regression Pesticide-Informed Liver Cancer Risk Score (PILCRS) and an Extreme Gradient Boosting (XGBoost) classifier that incorporated age, sex, alcohol use, occupation, and PLS. Internal validity used 1,000 bootstrap resamples with optimism-corrected calibration. Findings: Predicted CLD probability increased from 30% in the lowest PLS quartile to over 70% in the highest, and HCC from 10% to 40% (p<0ꞏ0001). Relative estimates were consistent; the highest versus lowest quartile yielded odds ratios of 2ꞏ84 (95% CI 1ꞏ66–4ꞏ91) for CLD and 4ꞏ76 (2ꞏ30– 10ꞏ29) for HCC. Cypermethrin remained independently associated. After optimism correction, both models demonstrated strong discrimination and calibration. Interpretation: This framework establishes a scalable, exposure-informed tool for liver disease prediction. Findings underscore pesticide burden as a modifiable risk factor and align with Sustainable Development Goal 3ꞏ9 and WHO–FAO priorities in low- and middle-income countries (LMICs). External validation is essential. Funding: National Institutes of Health (USA); Thailand Science Research and Innovation.

  • Beneficial infections of the enterovirus genus in patients with liver cancer

    by Lichun Ma, Man Hsin Hung, Farid Rashidi Mehrabadi, Limin Wang, Qin Li, Marshonna Forgues, Kathy Cheng Wang, Anuradha Budhu, Julián Candia, Jittiporn Chaisaingmongkol, et al.

    Background: Hepatocellular carcinoma (HCC) is a significant global cancer burden, with rising incidence and lacking a unified prevention strategy due to complex aetiologies. Viral exposures may shape host immunity via specific reactive viral antigens that could induce immune responses against hepatocarcinogenesis. Objective: We aimed to characterise viral exposure differences between HCC patients and healthy individuals and identify potentially protective viral antigens against HCC. Design: We profiled pan-viral serological antibody repertoires using a microbial phage library among 2647 study subjects and examined the biological activities of selective viral antigens on blood-derived immune cells from both healthy individuals and HCC patients. Result: We identified 153 viral antigens with a significantly reduced serological response in HCC patients compared with healthy individuals. We also observed that a higher serological response to 153 viral antigens is associated with better clinical outcomes of patients with chronic liver diseases and HCC. These findings are consistent across different populations across sex, ethnicity and aetiology. We identified a common epitope (CE1) shared among 39% of reactive viral antigens that belong to the rhinovirus and enterovirus families. We demonstrated that CE1 could induce both CD4 + and CD8 + T-cell activation and CD8 + T-cell-mediated HCC cell killing. Conclusions: Our results suggest that past exposures to members of the Enterovirus genus may be advantageous for cancer patients, highlighting the potential for a viral peptide-based HCC vaccine.


  • Open Access

    Reduction of alternative polarization of macrophages by short-term activated hepatic stellate cell-derived small extracellular vesicles

    by Yufeng Sun, Min Zhao, Li Cheng, Xiaoqian He, Shiqi Shen, Jiaying Lv, Junyu Zhang, Qian Shao, Wenxuan Yin, Fengbo Zhao, et al.

    Background: Activated hepatic stellate cells (HSCs) induce alternative (M2) polarization of macrophages and contribute to the progression of fibrosis and hepatocellular carcinoma (HCC). However, the effects of small extracellular vesicles released by HSCs (HSC-sEVs) during activation remain largely unknown. Methods: The aim of this study was to investigate the role of extracellular vesicles released by HSCs (HSC-sEVs) at different stages of activation in macrophage polarization. The effects of sEVs from short-term activated and long-term activated HSCs on liver macrophages was studied. Small RNA sequencing analyses were performed to obtain differential miRNAs transported by the short-term and long-term activated HSC- sEVs. The in vivo effects of short-term activated HSC-sEV-specific miRNA on liver macrophage and liver fibrosis were confirmed in a CCl4-induced liver injury mouse model. To study the tumor suppressive effects of the macrophages educated by short-term activated HSC-sEV-specific miRNA, human hepatoma cells were mixed and subcutaneously cotransplanted with miR-99a-5p mimic-pretreated macrophages. Results: We found that consistent with activated HSCs, long-term activated HSC-sEVs (14dHSC-sEVs) induce bone marrow-derived monocytes (MOs) toward an M2 phenotype, but short-term activated HSC-sEVs (3dHSC-sEVs) induce the resident macrophages (Kupffer cells, KCs) toward a classically activated (M1) phenotype. We identified five 3dHSC-sEV-specific miRNAs, including miR-99a-5p. In vitro and in vivo experiments support that miR-99a-5p negatively regulates alternative polarization of macrophages, decreases collagen deposition in chronic liver injury model, and suppresses the progression of hepatoma in a xenograft model partially by targeting CD93. Conclusion: Collectively, our work reveals an unexpected proinflammatory role of 3dHSC-sEVs, preliminarily explores the underlying mechanism, and evaluates the therapeutic potential of 3dHSC-sEV-specific miR-99a-5p for liver fibrosis and tumorigenesis.


  • Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME

    by Mohamed-Reda Benmebarek, Cihan Oguz, Matthias Seifert, Benjamin Ruf, Yuta Myojin, Kylynda C. Bauer, Patrick Huang, Chi Ma, Marina Villamor-Payà, Francisco Rodriguez-Matos, et al.


  • Open Access

    Associations of chronic liver disease and liver cancer with glyphosate and its metabolites in Thailand

    by Daxesh P. Patel, Christopher A. Loffredo, Benjarath Pupacdi, Siritida Rabibhadana, Panida Navasumrit, Jittiporn Chaisaingmongkol, Leila Toulabi, Majda Haznadar, Bhavik Dalal, Mohammed Khan, et al.

    Glyphosate [N‐(phosphonomethyl) glycine], a systemic herbicide, is used globally (825 million kg/year) in 750+ formulations. The International Agency for Research on Cancer classified glyphosate is a probable human carcinogen (Group 2A), but epidemiological studies have been lacking for its association with liver cancer and chronic liver disease. We analyzed urine specimens from 591 patients with newly diagnosed liver cancer, chronic liver disease (CLD), and healthy individuals from five different medical centers between 2011 to 2016 in Thailand. Gas chromatography electrospray ionization mass spectrometry (GC‐ESI/MS) was used to quantify glyphosate and its metabolites, aminomethylphosphonic acid (AMPA) and phosphoric acid (PPA) to study their levels in urine of hepatocellular carcinoma (HCC) and CLD patients in comparison to matched healthy individuals. Significantly higher levels of glyphosate were found in CLD patients compared to HCC cases and hospital controls, while significantly elevated levels of both AMPA and PPA were observed in HCC and CLD patients compared to hospital controls. Glyphosate and its metabolites were also detected at low to moderately high levels in convenience samples of food products and drinking water. These results raise concerns about the potential role of glyphosate in chronic liver disease and liver cancer risk.